Your browser doesn't support javascript.
loading
Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.
Kutsch, Nadine; Pallasch, Christian; Decker, Thomas; Hebart, Holger; Chow, Kai Uwe; Graeven, Ullrich; Kisro, Jens; Kroeber, Alexander; Tausch, Eugen; Fischer, Kirsten; Fink, Anna-Maria; Wendtner, Clemens-Martin; Ritgen, Matthias; Stilgenbauer, Stephan; Zhang, Danjie; Li, Biao; Jürgensmeier, Juliane M; Rajakumaraswamy, Nishanthan; Bhargava, Pankaj; Hallek, Michael; Eichhorst, Barbara.
Afiliação
  • Kutsch N; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany.
  • Pallasch C; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Germany.
  • Decker T; Onkologie Ravensburg, Ravensburg, Germany.
  • Hebart H; Clinics Ostalb, Stauferklinikum, Mutlangen, Germany.
  • Chow KU; Ambulantes Krebszentrum, Frankfurt, Germany.
  • Graeven U; Klinik für Hämatologie, Onkologie und Gastroenterologie, Kliniken Maria Hilf GmbH, Mönchengladbach, Germany.
  • Kisro J; Luebecker Onkologische Schwerpunktpraxis, Luebeck, Germany.
  • Kroeber A; Überörtliche Berufsausübungsgemeinschaft, Regensburg, Germany.
  • Tausch E; Department of Internal Medicine III, Ulm University, Germany.
  • Fischer K; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany.
  • Fink AM; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany.
  • Wendtner CM; Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilians-University, Munich, Germany.
  • Ritgen M; Department of Medicine II, University of Schleswig-Holstein, Kiel, Germany.
  • Stilgenbauer S; Department of Internal Medicine III, Ulm University, Germany.
  • Zhang D; Gilead Sciences, Inc., Foster City, CA, USA.
  • Li B; Gilead Sciences, Inc., Foster City, CA, USA.
  • Jürgensmeier JM; Gilead Sciences, Inc., Foster City, CA, USA.
  • Rajakumaraswamy N; Gilead Sciences, Inc., Foster City, CA, USA.
  • Bhargava P; Gilead Sciences, Inc., Foster City, CA, USA.
  • Hallek M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany.
  • Eichhorst B; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany.
Hemasphere ; 6(6): e729, 2022 Jun.
Article em En | MEDLINE | ID: mdl-35747845
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Hemasphere Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Hemasphere Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha